NASDAQ:MYLMylan Stock Price, Forecast & News

Mylan's stock was trading at $14.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MYL shares have increased by 13.0% and is now trading at $16.35.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Mylan.

Mylan is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Mylan.

Mylan NV (NASDAQ:MYL) released its earnings results on Thursday, August, 6th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.95 by $0.16. The company earned $2.73 billion during the quarter, compared to analysts' expectations of $2.74 billion. Mylan had a net margin of 0.54% and a return on equity of 20.00%. The firm's quarterly revenue was down 4.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.03 earnings per share.
View Mylan's earnings history.

Mylan updated its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.5-12 billion, compared to the consensus revenue estimate of $11.62 billion.

8 equities research analysts have issued 1 year price objectives for Mylan's shares. Their forecasts range from $17.00 to $27.00. On average, they anticipate Mylan's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 25.4% from the stock's current price.
View analysts' price targets for Mylan.

News articles about MYL stock have been trending very positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mylan earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Mylan.

Some companies that are related to Mylan include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (gild), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Starbucks (SBUX), Intel (INTC), Cisco Systems (CSCO) and CVS Health (CVS).

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Mylan's stock is owned by a variety of institutional and retail investors. Top institutional investors include Pzena Investment Management LLC (3.24%), Russell Investments Group Ltd. (0.63%), US Bancorp DE (0.56%), Swiss National Bank (0.39%), Retirement Systems of Alabama (0.24%) and First Trust Advisors LP (0.22%). Company insiders that own Mylan stock include Goulds Bruce, Melina E Higgins, Paul Campbell, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt.
View institutional ownership trends for Mylan.

MYL stock was sold by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, First Trust Advisors LP, Retirement Systems of Alabama, Robeco Institutional Asset Management B.V., Jabodon PT Co., Principal Financial Group Inc., Hartford Investment Management Co., and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Mylan.

MYL stock was bought by a variety of institutional investors in the last quarter, including US Bancorp DE, Russell Investments Group Ltd., State of Alaska Department of Revenue, SG Americas Securities LLC, Andra AP fonden, RMB Capital Management LLC, DekaBank Deutsche Girozentrale, and Hussman Strategic Advisors Inc.. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury, and Sjoerd S Vollebregt.
View insider buying and selling activity for Mylan.

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MYL stock can currently be purchased for approximately $16.35.

Mylan has a market capitalization of $8.45 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

The official website for Mylan is www.mylan.com.

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]